IL6R and metabolic syndrome: Our IL6R polymorphism results suggest that, during the treatment of patients with active RA with tocilizumab, rs4845625 is associated with the development of dyslipidemia, and rs11255618 and rs4329505 are associated with the development of hematological effects.